Colorectal Cancer Immunotherapy: Options and Strategies

Johdi, Nor Adzimah; Sukor, Nur Fazilah

doi:10.3389/fimmu.2020.01624

Cited by 297 publications

(221 citation statements)

References 212 publications

(220 reference statements)

Supporting

Mentioning

216

Contrasting

Unclassified

Order By: Relevance

“…Although overall mortality rates continue to decline due to improvements in diagnosis and treatment, the survival rate for advanced disease remains low and approximately 50% of patients relapse even after additional treatment with neoadjuvant therapy (Ogura et al, 2019). Cancer immunotherapy is a new alternative for cancer treatment that overcomes the non-specific problems associated with radiotherapy and chemotherapy (Johdi and Sukor, 2020). Hence, it is important to find a suitable immunity-related prognostic biomarker for CRC and to identify patients who can benefit from anti-tumor immunotherapy.…”

Section: Discussionmentioning

confidence: 99%

“…The standard methods for CRC treatment are surgery, chemotherapy, and radiotherapy. These treatments can be combined, depending on the location and progression of the cancer (Johdi and Sukor, 2020). For example, approximately 66-61% of stage II and stage III patients with colon and rectal cancer undergo further treatments with adjuvant chemotherapy and/or radiotherapy, respectively (Miller et al, 2019).…”

Section: Introductionmentioning

confidence: 99%

“…Cancer immunotherapy targets specific cancer antigens on the malignant cells, alerting the immune system to eradicate cancer through concerted immune responses (Johdi and Sukor, 2020).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Immune-Related Gene Expression Analysis Revealed Three lncRNAs as Prognostic Factors for Colon Cancer

et al. 2021

View full text Add to dashboard Cite

Colorectal cancer (CRC) is one of the most common cancers. Almost 80% of CRC cases are colon adenocarcinomas (COADs). Several studies have indicated the role of immunotherapy in the treatment of various cancers. Our study aimed to identify immune-related long non-coding RNAs (lncRNAs) and to use them to construct a risk assessment model for evaluating COAD prognosis. Using differential expression, correlation, and Cox regression analyses, we identified three immune-related differentially expressed lncRNAs (IR-DELs) and used them to construct a risk assessment model. The area under the curve (AUC) for each receiver operating characteristic (ROC) curve at 3-, 5-, and 10-years were greater than 0.6. In addition, the risk assessment model was correlated with several immune cells and factors. The three IR-DELs (AC124067.4, LINC02604, and MIR4435-2HG) identified in this study can be used to predict outcomes for patients with COAD and might help in identifying those who can benefit from anti-tumor immunotherapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Immune-Related Gene Expression Analysis Revealed Three lncRNAs as Prognostic Factors for Colon Cancer

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Unfortunately, chemotherapy and radiotherapy are characterized by low specificity and significant systemic cytotoxicity as well as by unsatisfying recurrence rates. Therefore, research has been directed to better knowing CRC immunogenic potential and the development of targeted therapy[ 45 ].…”

Section: B7-h3 In Crcmentioning

confidence: 99%

B7 homologue 3 as a prognostic biomarker and potential therapeutic target in gastrointestinal tumors

Rasic¹,

Jovanović-Tucović²,

Jeremic³

et al. 2021

WJGO

View full text Add to dashboard Cite

The most common digestive system (DS) cancers, including tumors of the gastrointestinal tract (GIT) such as colorectal cancer (CRC), gastric cancer (GC) and esophageal cancer (EC) as well as tumors of DS accessory organs such as pancreatic and liver cancer, are responsible for more than one-third of all cancer-related deaths worldwide, despite the progress that has been achieved in anticancer therapy. Due to these limitations in treatment strategies, oncological research has taken outstanding steps towards a better understanding of cancer cell biological complexity and heterogeneity. These studies led to new molecular target-driven therapeutic approaches. Different in vivo and in vitro studies have revealed significant expression of B7 homologue 3 (B7-H3) among the most common cancers of the GIT, including CRC, GC, and EC, whereas B7-H3 expression in normal healthy tissue of these organs was shown to be absent or minimal. This molecule is able to influence the biological behavior of GIT tumors through the various immunological and nonimmunological molecular mechanisms, and some of them are shown to be the result of B7-H3-related induction of signal transduction pathways, such as Janus kinase 2/signal transducer and activator of transcription 3, phosphatidylinositol 3-kinase/protein kinase B, extracellular signal-regulated kinase, and nuclear factor-κB. B7-H3 exerts an important role in progression, metastasis and resistance to anticancer therapy in these tumors. In addition, the results of many studies suggest that B7-H3 stimulates immune evasion in GIT tumors by suppressing antitumor immune response. Accordingly, it was observed that experimental depletion or inhibition of B7-H3 in gastrointestinal cancers improved antitumor immune response, impaired tumor progression, invasion, angiogenesis, and metastasis and decreased resistance to anticancer therapy. Finally, the high expression of B7-H3 in most common cancers of the GIT was shown to be associated with poor prognosis. In this review, we summarize the established data from different GIT cancer-related studies and suggest that the B7-H3 molecule could be a promising prognostic biomarker and therapeutic target for anticancer immunotherapy in these tumors.

show abstract

“…Colorectal cancer. Colorectal cancer (CRC) is one of the most common types of cancer worldwide and has incidence and mortality rates globally (119,120). ART was found to inhibit CRC proliferation and promote apoptosis in a dose-dependent manner to significantly suppress the growth of colorectal tumors, decrease the physiological activity of cancer and delay spontaneous liver metastasis in the CLY CRC cell line.…”

Section: Potential Role Of Art In Human Malignanciesmentioning

confidence: 99%

Progress on the study of the anticancer effects of artesunate (Review)

et al. 2021

View full text Add to dashboard Cite

Artesunate (ART) is a derivative of artemisinin that is extracted from the wormwood plant Artemisia annua. ART is an antimalarial drug that has been shown to be safe and effective for clinical use. In addition to its antimalarial properties, ART has been attracting attention over recent years due to its reported inhibitory effects on cancer cell proliferation, invasion and migration. Therefore, ART has a wider range of potential clinical applications than first hypothesized. The aim of the present review was to summarize the latest research progress on the possible anticancer effects of ART, in order to lay a theoretical foundation for the further development of ART as a therapeutic option for cancer. Contents1. Introduction 2. Source and activity of ART 3. Anticarcinogenic mechanism of ART 4. Potential role of ART in human malignancies 5. Summary and perspectives

show abstract

Colorectal Cancer Immunotherapy: Options and Strategies

Cited by 297 publications

References 212 publications

Immune-Related Gene Expression Analysis Revealed Three lncRNAs as Prognostic Factors for Colon Cancer

Immune-Related Gene Expression Analysis Revealed Three lncRNAs as Prognostic Factors for Colon Cancer

B7 homologue 3 as a prognostic biomarker and potential therapeutic target in gastrointestinal tumors

Progress on the study of the anticancer effects of artesunate (Review)

Contact Info

Product

Resources

About